DWTX vs. ELUT, LVTX, TPST, JATT, TLPH, XLO, GBIO, JSPR, DYAI, and VRCA
Should you be buying Dogwood Therapeutics stock or one of its competitors? The main competitors of Dogwood Therapeutics include Elutia (ELUT), LAVA Therapeutics (LVTX), Tempest Therapeutics (TPST), JATT Acquisition (JATT), Talphera (TLPH), Xilio Therapeutics (XLO), Generation Bio (GBIO), Jasper Therapeutics (JSPR), Dyadic International (DYAI), and Verrica Pharmaceuticals (VRCA). These companies are all part of the "pharmaceutical products" industry.
Dogwood Therapeutics vs. Its Competitors
Elutia (NASDAQ:ELUT) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.
74.0% of Elutia shares are owned by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are owned by institutional investors. 27.6% of Elutia shares are owned by insiders. Comparatively, 3.9% of Dogwood Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Dogwood Therapeutics has a net margin of 0.00% compared to Elutia's net margin of -90.01%.
Dogwood Therapeutics has lower revenue, but higher earnings than Elutia. Elutia is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.
Elutia currently has a consensus target price of $7.00, indicating a potential upside of 689.18%. Dogwood Therapeutics has a consensus target price of $12.00, indicating a potential upside of 73.76%. Given Elutia's stronger consensus rating and higher probable upside, equities research analysts clearly believe Elutia is more favorable than Dogwood Therapeutics.
Elutia has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500. Comparatively, Dogwood Therapeutics has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500.
In the previous week, Dogwood Therapeutics had 13 more articles in the media than Elutia. MarketBeat recorded 16 mentions for Dogwood Therapeutics and 3 mentions for Elutia. Dogwood Therapeutics' average media sentiment score of 0.54 beat Elutia's score of 0.50 indicating that Dogwood Therapeutics is being referred to more favorably in the news media.
Summary
Elutia and Dogwood Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.
Get Dogwood Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DWTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding DWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dogwood Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:DWTX) was last updated on 10/7/2025 by MarketBeat.com Staff
